Effect of Inpatient Diabetes Management on Outpatient Glycemic Control
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Diabetes management team
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years
- Known diagnosis of type 2 diabetes by history with outpatient prescription of oral hypoglycemic medication or insulin
- Hemoglobin A1c > 8.0% within the prior 12 months, or if not known, fasting blood glucose greater than 200 mg/dl on sliding scale regular insulin.
- Partners-affiliated primary care physician
Exclusion Criteria:
- Screening HbA1c returns less than 8%.
- Diabetic ketoacidosis (DKA) as a primary reason for admission (admission blood glucose > 250 mg/dl with arterial pH < 7.30 or serum bicarbonate level < 15 mg/dl), or development of DKA during admission.
- Hyperosmolar hyperglycemic syndrome as a primary reason for admission (admission blood glucose > 400 mg/dl and plasma osmolality > 315 mOsm/kg.
- Pregnancy, ruled out by urine HCG test at screening after consent is obtained in all women who continue to have menstrual cycles.
- Anemia with hemoglobin < 9 g/dl, recent blood transfusion, or need for blood transfusion (interferes with interpretation of hemoglobin A1c assay)
- End stage liver disease with prothrombin time > 15 seconds and albumin <3 mg/dl
- End stage renal disease: Stage IV (glomerular filtration rate <30 mg/dl) or V chronic kidney disease
- Treatment with corticosteroids
- ICU transfer
- Inability to self-administer insulin
- Hypoglycemia unawareness: patient lacks sensation of common signs of blood glucose < 60 mg/dl (tachycardia, diaphoresis, hunger, confusion, fatigue).
- Projected survival < 1 year
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Diabetes Management Team
Control
Arm Description
Evaluation and management by diabetes management team
Patients receive usual care for diabetes
Outcomes
Primary Outcome Measures
Hemoglobin A1c
Change in glycemic control measured by HbA1c change baseline to 6 months
Secondary Outcome Measures
Average Intervention Effect Over 12 Months After Hospital Discharge
Full Information
NCT ID
NCT00869362
First Posted
March 25, 2009
Last Updated
October 27, 2014
Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1. Study Identification
Unique Protocol Identification Number
NCT00869362
Brief Title
Effect of Inpatient Diabetes Management on Outpatient Glycemic Control
Official Title
Effect of Inpatient Diabetes Management on Outpatient Glycemic Control
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The hypothesis of this study is that using hospital admission to identify patients with poorly controlled diabetes (hemoglobin A1c levels >8%), and intervening during the hospitalization with targeted inpatient diabetes management will improve glycemic control at 3 and 12 months, with inpatient glycemic control, quality of life, and diabetes self-efficacy serving as secondary endpoints.
Detailed Description
The study is a randomized, controlled trial of targeted inpatient diabetes management versus usual care in 70 general medical and surgical inpatients over age 18 with type 2 diabetes and hemoglobin A1c levels greater than 8% who are followed in Partners-affiliated primary care practices. In addition, we will enroll a prospective chart review cohort matched for age, sex, and HbA1c level whose course we will follow for one year after discharge to determine the patter of glycemia among patients who are not enrolled in a clinical trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
31 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diabetes Management Team
Arm Type
Experimental
Arm Description
Evaluation and management by diabetes management team
Arm Title
Control
Arm Type
No Intervention
Arm Description
Patients receive usual care for diabetes
Intervention Type
Other
Intervention Name(s)
Diabetes management team
Intervention Description
MD evaluation followed by NP education and and medication titration
Primary Outcome Measure Information:
Title
Hemoglobin A1c
Description
Change in glycemic control measured by HbA1c change baseline to 6 months
Time Frame
6 months from discharge
Secondary Outcome Measure Information:
Title
Average Intervention Effect Over 12 Months After Hospital Discharge
Time Frame
12 months from discharge
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > 18 years
Known diagnosis of type 2 diabetes by history with outpatient prescription of oral hypoglycemic medication or insulin
Hemoglobin A1c > 8.0% within the prior 12 months, or if not known, fasting blood glucose greater than 200 mg/dl on sliding scale regular insulin.
Partners-affiliated primary care physician
Exclusion Criteria:
Screening HbA1c returns less than 8%.
Diabetic ketoacidosis (DKA) as a primary reason for admission (admission blood glucose > 250 mg/dl with arterial pH < 7.30 or serum bicarbonate level < 15 mg/dl), or development of DKA during admission.
Hyperosmolar hyperglycemic syndrome as a primary reason for admission (admission blood glucose > 400 mg/dl and plasma osmolality > 315 mOsm/kg.
Pregnancy, ruled out by urine HCG test at screening after consent is obtained in all women who continue to have menstrual cycles.
Anemia with hemoglobin < 9 g/dl, recent blood transfusion, or need for blood transfusion (interferes with interpretation of hemoglobin A1c assay)
End stage liver disease with prothrombin time > 15 seconds and albumin <3 mg/dl
End stage renal disease: Stage IV (glomerular filtration rate <30 mg/dl) or V chronic kidney disease
Treatment with corticosteroids
ICU transfer
Inability to self-administer insulin
Hypoglycemia unawareness: patient lacks sensation of common signs of blood glucose < 60 mg/dl (tachycardia, diaphoresis, hunger, confusion, fatigue).
Projected survival < 1 year
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deborah J Wexler, MD, MSc
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
23036785
Citation
Wexler DJ, Beauharnais CC, Regan S, Nathan DM, Cagliero E, Larkin ME. Impact of inpatient diabetes management, education, and improved discharge transition on glycemic control 12 months after discharge. Diabetes Res Clin Pract. 2012 Nov;98(2):249-56. doi: 10.1016/j.diabres.2012.09.016. Epub 2012 Oct 1.
Results Reference
result
Learn more about this trial
Effect of Inpatient Diabetes Management on Outpatient Glycemic Control
We'll reach out to this number within 24 hrs